Bisphosphonates in the Adjuvant Treatment of Breast Cancer

Clinical Oncology

Volumn 25, Issue 2, 2013, Pages 135-145

  Winter, M C ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Anti tumour activity; Bisphosphonates; Breast cancer; Clodronate; Zoledronic acid

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; HUMAN; METASTASIS; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES;

EID: 84872395940     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.10.010     Document Type: Article

References (68)

1. Pavlakis N., Schmidt R., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005, CD003474.
2. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
3. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.
4. Russell R.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
5. Benford H.L., Frith J.C., Auriola S., Monkkonen J., Rogers M.J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56:131-140.
6. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
7. Hadji P., Gnant M., Body J.J., et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. Cancer Treat Rev 2012, 38(6):798-806.
8. Reid D.M., Doughty J., Eastell R., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 2008, 34(Suppl. 1):S3-18.
9. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718-1729.
10. Lester J., Dodwell D., McCloskey E., Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 2005, 31:115-142.
11. Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26:4739-4745.
12. Kim J.E., Ahn J.H., Jung K.H., et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 2011, 125:99-106.
13. Shapiro C.L., Halabi S., Hars V., et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011, 47:683-689.
14. Hines S.L., Mincey B.A., Sloan J.A., et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009, 27:1047-1053.
15. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
16. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008, 26:1051-1057.
17. Eastell R., Adams J., Clack G., et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2010, 22:857-862.
18. Coleman R.E., Banks L.M., Girgis S.I., et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010, 124:153-161.
19. Hadji P., Aapro M.S., Body J.J., et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011, 22:2546-2555.
20. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
21. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008, 112:1001-1010.
22. Llombart A., Frassoldati A., Paija O., et al. immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012, 12:40-48.
23. Hines S.L., Mincey B., Dentchev T., et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009, 117:603-609.
24. Llombart A, Frassoldati A, Paija O. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36 month follow-up. American Society of Clinical Oncology Breast Cancer Symposium Abstract 213. San Francisco, 2009.
25. Brufsky A.M., Harker W.G., Beck J.T., et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012, 118:1192-1201.
26. De Boer R., Bundred N., Eidtmann H., et al. The effect of zoledronic acid on aromatase-inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. Cancer Res 2011, 70(24 Suppl.). abstract P5-11-01.
27. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
28. Markopoulos C., Tzoracoleftherakis E., Polychronis A., et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 2010, 12:R24.
29. Van Poznak C., Hannon R.A., Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975.
30. Hadji P., Body J.J., Aapro M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.
31. Winter M.C., Holen I., Coleman R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475.
32. Daubine F., Le Gall C., Gasser J., Green J., Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99:322-330.
33. Sasaki A., Boyce B.F., Story B., et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995, 55:3551-3557.
34. Sasaki A., Kitamura K., Alcalde R.E., et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 1998, 77:279-285.
35. Hiraga T., Williams P.J., Ueda A., Tamura D., Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10:4559-4567.
36. Ottewell P.D., Lefley D.V., Cross S.S., Evans C.A., Coleman R.E., Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2009, 126(2):522-532.
37. Ottewell P.D., Monkkonen H., Jones M., Lefley D.V., Coleman R.E., Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100:1167-1178.
38. Dieli F., Gebbia N., Poccia F., et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102:2310-2311.
39. Kunzmann V., Bauer E., Feurle J., Weissinger F., Tony H.P., Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
40. Aft R., Naughton M., Trinkaus K., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
41. Rack B., Juckstock J., Genss E.M., et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
42. Solomayer E.F., Gebauer G., Hirnle P., et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012, 23(9):2271-2277.
43. Diel I.J., Jaschke A., Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
44. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
45. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
46. Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
47. Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
48. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
49. Ha T.C., Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007, 96:1796-1801.
50. Kristensen B., Ejlertsen B., Mouridsen H.T., et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008, 47:740-746.
51. Paterson A.H., Anderson S.J., Lembersky B.C., et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012, 13(7):734-742.
52. Mobus V., Diel I.J., Elling D., et al. GAIN study: a phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis. Cancer Res 2011, 71(24 Suppl.). abstract S2-S4.
53. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
54. Gnant M., Mlineritsch B., Stoeger H., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641.
55. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in pre-menopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res 2011, 71(24 Suppl.). abstract S1-S2.
56. de Boer R., Bundred N., Eidtmann H., et al. Long-term survival outcome among post-menopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid; 5-year follow-up of ZO-FAST. Cancer Res 2011, 71(24 Suppl.). abstract S1-S3.
57. Brufsky A, Harker WG, Beck JT, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in post-menopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Presented at the 2009 San Antonio Breast Cancer Symposium Abstract 4083, 2009.
58. Coleman RE, Bundred N, De Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant zoledronic acid: Z-FAST, ZO-FAST and EZO-FAST. San Antonio Breast Cancer Symposium, 2009, abstract 4082, San Antonio, TX, 2009.
59. Coleman R.E., Marshall H., Cameron D., et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405.
60. Coleman R., Woodward E., Brown J., et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 2011, 127:429-438.
61. Gregory W., Marshall H., Bell R., Cameron D.A., Coleman R.E. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis. J Clin Oncol 2012, 30(Suppl.). abstract 513.
62. Wilson C., Holen I., Coleman R.E. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012, 38(7):877-889.
63. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
64. Coleman R., Burkinshaw R., Winter M., et al. Zoledronic acid. Expert Opin Drug Saf 2011, 10:133-145.
65. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
66. National Institute for Health and Clinical Excellence. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE technology appraisal guidance 265. [accessed 13.11.12]. http://guidance.nice.org.uk/265.
67. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy. [accessed 17.09.12]. ctgov:NCT00556374.
68. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). [accessed 17.09.12]. ctgov:NCT01077154.